Kishore Harjai, MD
Interventional Cardiology · Macon, GANPI 1588631212
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Edwards Lifesciences at 31.6% of the total. Reporting peaked in 2019 at $11,920 and has fallen 81.7% since, to $2,184 in 2025.
Across 228 payments — averaging $174.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$13K
- Cardinal Health 200 LLC$8K
- Boston Scientific$7K
- Abbott$6K
- Abiomed$2K
- Medtronic$2K
- plus $3K from 18 others
Across 78 payments — averaging $2426.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$69K
- Abbott$66K
- Daiichi Sankyo Inc.$24K
- Bayer$21K
- Cardiovascular Systems Inc.$9K
What the payments were for
- Consulting fees$15,66339%
- Travel & lodging$11,12328%
- Food & beverage$12,98933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 48 | $12,578 |
| Cardinal Health 200 LLC | 7 | $7,711 |
| Boston Scientific | 26 | $7,082 |
| Abbott | 63 | $5,629 |
| Abiomed | 24 | $2,012 |
| Medtronic(2 entities) | 16 | $1,638 |
| Philips North America LLC | 5 | $733 |
| Biotronik Inc. | 3 | $380 |
| Cvrx, Inc. | 3 | $367 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $355 |
| Siemens Medical Solutions USA, Inc. | 1 | $174 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| AstraZeneca | 1 | $117 |
| Johnson & Johnson | 1 | $117 |
| Coala Life Inc | 1 | $114 |
| Shockwave Medical, Inc | 2 | $113 |
| Novartis | 6 | $110 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $110 |
| Livanova USA, Inc. | 1 | $107 |
| Pfizer | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Heartflow, Inc. | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$11,113
- GENERAL VASCULAR ACCESS$5,274
- MitraClip$1,623
- Impella$1,495
- GENERAL - THERAPIES$1,173
- TRICLIP$1,115
- COREVALVE EVOLUT R$653
- (9520) IGT Devices Undivided$579
- Barostim Neo System$314
- Micra$312
- CARDIOMEMS$267
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$258
- Acticor$255
- BioMonitor$255
- Edora$255
- Solia$255
- Rivacor$255
- XARELTO$238
- AMPLATZER$173
- AZURE XT DR MRI SURESCAN$155
How this compares
$39,775 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $42,248 |
| EntrestoSacubitril/Valsartan | 17 | $24,594 |
| Metoprolol Succinate | 28 | $312 |
| Metoprolol Tartrate | 23 | $288 |
| Carvedilol | 13 | $131 |
| ClopidogrelClopidogrel Bisulfate | 22 | $122 |
| Atorvastatin Calcium | 45 | $117 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $74 |
| Furosemide | 20 | $65 |
| Prednisone | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $99 | $42,24837 claims |
| NovartisEntresto | $110 | $24,59417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Macon
- Gary DanielMacon$28K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.